Articles tagged with Steatohepatitis
SLC transporters contribute to the development of hepatic steatosis by regulating lipid metabolism, particularly with SLC2A2, GLUT4, and GLUT5. These proteins influence processes like de novo lipogenesis and insulin resistance in hepatocytes.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
This study investigates SOX9's role in MASH pathogenesis and explores its underlying mechanisms. SOX9 overexpression alleviates hepatic lipid accumulation by activating the AMPK pathway.
Overexpressing hepatic SLC7A11 leads to glutamate and serine deficiency, promoting MASLD progression through ferroptosis. Serine supplementation rescues the disease phenotype.
Researchers discovered a novel combination of plasma-based biomarkers that can predict liver fibrosis in Latino adolescents with obesity. The study found that dihydroxyacetone phosphate (DHAP) and alanine transaminase (ALT) were significantly associated with fibrosis, suggesting a potential low-cost, noninvasive screening tool.
Researchers have identified three major pathomechanisms of MASLD: hepatic genetic component, metabolic de novo lipogenesis, and adipose tissue dysfunction. These subtypes have distinct risk factors for cardiovascular disease and type 2 diabetes. Novel pharmacological approaches may facilitate targeted therapies for each subtype.
GLP-1RAs improve liver histology, reduce liver fat, and enhance metabolic parameters in MASLD patients. However, challenges remain in assessing long-term liver benefits and clarifying the effects on liver fibrosis.
A new study has identified two distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASH) with similar histological features but different clinical outcomes. The research empowers clinicians to adopt subtype-specific treatments leveraging simple clinical markers, offering a clear path to improve patient outcomes.
A new study proves a suspected link between poor sleep and MASLD, a liver disorder that affects 30% of adults. Patients with MASLD experience significant sleep fragmentation, waking up 55% more often at night.
A new study reveals that an AI algorithm can accurately detect early-stage metabolic-associated steatotic liver disease (MASLD) in patients who meet the criteria, leaving 83% undiagnosed. This highlights the need for improved screening and diagnosis methods to prevent progression to advanced liver disease.
The 17-beta-hydroxysteroid dehydrogenase 13 gene plays a significant role in regulating liver lipid metabolism, with loss-of-function variants linked to reduced risk of chronic liver disease progression. HSD17B13 modulation may provide therapeutic benefits for individuals with metabolic liver disease.
A U.S.-based single-center retrospective cohort study found that advanced liver fibrosis is a primary risk factor for incident liver decompensation and liver-related events in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. The study, published in the Journal of Clinical and Translational Hepatolog...
Metabolic dysfunction-associated steatohepatitis (MASLD) exhibits persistent activation of the DNA damage response (DDR) and its primary transcription factor P53 even after dietary reversal. Elevated P53 levels correlate with hepatocyte ballooning, suggesting a link between DDR signaling and MASLD recurrence.
Researchers found inhibiting ACMSD increases NAD+ levels, reducing inflammation and fibrosis in mouse models of MASLD/MASH. Boosting NAD+ production could protect against severe liver damage and cirrhosis.
Researchers explore antidiabetic agents, PPAR agonists, FXR agonists, and other novel compounds to target MASLD pathogenesis. Combination therapies may enhance therapeutic efficacy while minimizing side effects, offering new hope to patients at risk of advanced liver disease.